179 related articles for article (PubMed ID: 21659969)
1. Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect.
Med Lett Drugs Ther; 2011 Jun; 53(1366):46-7. PubMed ID: 21659969
[No Abstract] [Full Text] [Related]
2. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
Patatanian E; Casselman J
Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
[TBL] [Abstract][Full Text] [Related]
3. A naturalistic on-off-on trial of dextromethorphan/quinidine for agitation associated with cerebellar injury.
Daly JP; Caplan JP
Psychosomatics; 2012; 53(5):470-3. PubMed ID: 22458990
[No Abstract] [Full Text] [Related]
4. Dextromethorphan/quinidine sulfate for pseudobulbar affect.
Rosen H
Drugs Today (Barc); 2008 Sep; 44(9):661-8. PubMed ID: 19137121
[TBL] [Abstract][Full Text] [Related]
5. NueDexta: A Treatment for Pseudobulbar Affect.
Roman MW
Issues Ment Health Nurs; 2015; 36(12):1019-21. PubMed ID: 26735510
[No Abstract] [Full Text] [Related]
6. Treatment of pseudobulbar affect in ALS.
Smith RA; Brooks BR
Lancet Neurol; 2005 May; 4(5):270. PubMed ID: 15847840
[No Abstract] [Full Text] [Related]
7. Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?
Stahl SM
CNS Spectr; 2016 Dec; 21(6):419-423. PubMed ID: 27855728
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
Fralick M; Sacks CA; Kesselheim AS
JAMA Intern Med; 2019 Feb; 179(2):224-230. PubMed ID: 30615021
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pseudobulbar affect in ALS: October 26 highlight and commentary.
Hingorani VN; Kittrelle JP
Neurology; 2005 May; 64(10):1821; author reply 1821. PubMed ID: 15911831
[No Abstract] [Full Text] [Related]
10. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients.
Wahler RG; Reiman AT; Schrader JV
J Palliat Med; 2017 Mar; 20(3):294-297. PubMed ID: 27997281
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.
Miller A; Panitch H
J Neurol Sci; 2007 Aug; 259(1-2):67-73. PubMed ID: 17433820
[TBL] [Abstract][Full Text] [Related]
12. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
[TBL] [Abstract][Full Text] [Related]
14. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
[TBL] [Abstract][Full Text] [Related]
15. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
[TBL] [Abstract][Full Text] [Related]
17. Dextromethorphan/quinidine: in pseudobulbar affect.
Garnock-Jones KP
CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
[TBL] [Abstract][Full Text] [Related]
18. Recognizing and treating pseudobulbar affect.
Sauvé WM
CNS Spectr; 2016 Dec; 21(S1):34-44. PubMed ID: 28044945
[TBL] [Abstract][Full Text] [Related]
19. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
Yang LP; Deeks ED
Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
[TBL] [Abstract][Full Text] [Related]
20. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.
Miller A; Pratt H; Schiffer RB
Expert Rev Neurother; 2011 Jul; 11(7):1077-88. PubMed ID: 21539437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
